A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Trial Profile

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOWER
  • Sponsors Sanofi
  • Most Recent Events

    • 19 Jun 2018 Results of pooled data from TEMSO, TOWER, TOPIC and TENERE trials presented at the 4th Congress of the European Academy of Neurology.
    • 19 Jun 2018 Results of pooled analysis of the phase-3 TEMSO and TOWER studies presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of a subgroup analysis from ADVANCE, ATTAIN, TEMSO and TOWER studies comparing the clinical outcomes of peginterferon beta-1a and teriflunomide in DMT niave RMS patients, presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top